News | September 01, 2008

Study Finds Diabetic Patients With Complex Heart Disease Can Safely Choose PCI

September 2, 2008 - Patients with both diabetes and advanced blockages in at least three heart vessels will find good news in new findings announced from the CARDia trial, said the Society for Cardiovascular Angiography and Interventions (SCAI)

The one-year findings of the new study indicate these patients can safely choose to undergo angioplasty and stenting rather than open-heart surgery.

At the European Society of Cardiology Congress in Munich, Germany, investigators from the U.K. presented the results of CARDia (Coronary Artery Revascularization in Diabetes), a clinical trial comparing percutaneous coronary intervention (PCI) vs. open-heart surgery in patients typically considered to be poor candidates for angioplasty and stenting. Since the combination of diabetes and multi-vessel coronary artery disease has long been considered the domain of surgeons, their findings surprised some. The patients who underwent PCI rather that surgery did just as well as the surgery patients on the primary endpoint of death, heart attack, and stroke, according to the study. In addition, the PCI patients experienced fewer strokes and less bleeding.

This finding differs from earlier trials comparing PCI and surgery in these patients, perhaps because drug-eluting stents have been added to the mix, suggest SCAI leaders.

“The take-away message is that diabetic patients with complex coronary artery disease may now be able to choose angioplasty and stenting over bypass surgery,” said Dr. Bonnie Weiner, SCAI immediate past-president, professor of medicine, and director of interventional cardiology research at St. Vincent Hospital at Worcester Medical Center, Worcester, MA. “It’s important to realize that this is one trial and the first-year findings, but it’s a good sign for patients because it could ultimately broaden their options.”

CARDia also examined whether, after undergoing PCI or surgery, patients required a repeat procedure. The difference in repeat revascularization between PCI and bypass surgery was very small but statistically significant, despite an unusually low rate for both groups (9.9 percent for PCI vs. 2 percent for bypass). Further, when the patients who received drug-eluting stents (rather than bare metal stents or the entire study population) were specifically analyzed, the difference in revascularization in the PCI group was even lower, and the difference in the rates of repeat revascularization was less important (7.3 percent for PCI vs. 2 percent for bypass). This represented about two-thirds of the study population and more closely reflects current practices.

For more information: www.scai.org, www.seconds-count.org

Related Content

CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Sponsored Content | Videos | Peripheral Artery Disease (PAD)| July 25, 2017
This video case study, provided by Gore Medical, is titled "Tackling Complex Cases in Dialysis Access," by John Ross,
Sponsored Content | Videos | Cardiovascular Surgery| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
tandemLife Tandemheart priming tray cleared by FDA
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — TandemLife began its commercial launch of the TandemLife Priming Tray, a new product designed to simp
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
Overlay Init